Show simple item record

dc.contributor.authorKraja, Aldi T.en_US
dc.contributor.authorBorecki, Ingrid B.en_US
dc.contributor.authorNorth, Karien_US
dc.contributor.authorTang, Weihongen_US
dc.contributor.authorMyers, Richard H.en_US
dc.contributor.authorHopkins, Paul N.en_US
dc.contributor.authorArnett, Donnaen_US
dc.contributor.authorCorbett, Jonathanen_US
dc.contributor.authorAdelman, Avrilen_US
dc.contributor.authorProvince, Michael A.en_US
dc.date.accessioned2012-01-11T21:09:07Z
dc.date.available2012-01-11T21:09:07Z
dc.date.copyright2006
dc.date.issued2006-12-5
dc.identifier.citationKraja, Aldi T, Ingrid B Borecki, Kari North, Weihong Tang, Richard H Myers, Paul N Hopkins, Donna Arnett, Jonathan Corbett, Avril Adelman, Michael A Province. "Longitudinal and age trends of metabolic syndrome and its risk factors: The Family Heart Study" Nutrition & Metabolism 3:41. (2006)
dc.identifier.issn1743-7075
dc.identifier.urihttp://hdl.handle.net/2144/3182
dc.description.abstractBACKGROUND. We report longitudinal changes in the metabolic syndrome (MetS) in 2,458 participants from 480 families in the Family Heart Study. Participants were examined between 1994–96 (FHS-T1) and 2002–03 (FHS-T2), about 7.4 years apart. Additionally, the impact of medication on estimates of MetS prevalence, and associations of MetS with prevalent coronary heart disease (CHD) and type 2 diabetes (T2D) were studied. METHODS. Three definitions for MetS prevalence were considered. One represented the original (o) National Cholesterol Education Program (NCEP) MetS criteria. Two others considered the confounding of medications effects, respectively (m) lipid medications constituted a categorical diagnostic criterion for lipids variables, and (c) lipids and blood pressure variables were corrected with average clinical trials medications effects. Logistic regression of MetS on CHD and T2D, as well as the trend analysis of MetS by age, were performed. RESULTS. MetS increased from 17.1% in FHS-T1(o) to 28.8% in FHS-T2(o); from 19.7% in FHS-T1(m) to 42.5% in FHS-T2(m); and from 18.4% in FHS-T1(c) to 33.6% in FHS-T2(c). While we observed adverse changes in all risk factors, the greatest increase was for waist circumference (25%). The percentages of MetS were about 2 to almost 3 times higher in ages 50 years and older than in younger ages. The odds of having prevalent CHD were about 2.5 times higher in the subjects classified with MetS than without. CONCLUSION. MetS percentages increased noticeably longitudinally and cross-sectionally with older age. These conclusions were reached with and without considering medication use, but correcting risk factors for medications use affects the MetS prevalence estimates. As found in other studies, MetS was associated with increased odds for prevalent CHD.en_US
dc.description.sponsorshipNational Heart, Lung, and Blood Institute (U01 HL56563, U01 HL56564, U01 HL56565, U01 HL56566, U01 HL56567, U01 HL56568, U01 HL56569, 5K01-HL70444).en_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2006 Kraja et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.titleLongitudinal and Age Trends of Metabolic Syndrome and Its Risk Factors: The Family Heart Studyen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1743-7075-3-41
dc.identifier.pubmedid17147796
dc.identifier.pmcid1697811


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2006 Kraja et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2006 Kraja et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.